Equity, diversity and inclusion in DMD
The objectives of this symposium are the following:
1.Explain how equity, diversity and inclusion could impact diagnosis, access to treatments and treatment outcomes in patients with rare neuromuscular conditions, such as Duchenne muscular dystrophy (DMD)
2.Understand the benefits of including diverse populations in clinical trials
3.Understand potential barriers to participation in clinical trials of DMD and discuss effective strategies to recruit, enroll, and retain racially and ethnically diverse populations.